bioAffinity Technologies Secures Patent for CyPath Lung Cancer Diagnostic in Hong Kong
bioAffinity Technologies has been granted a patent by the Hong Kong Intellectual Property Department covering core technology used in its noninvasive lung cancer diagnostic, CyPath Lung. The new patent complements an existing Chinese patent from 2025 and strengthens the company's intellectual property position across Asia. CyPath Lung uses flow cytometry and fluorescent markers to assess malignancy risk in patients with suspicious lung nodules detected via CT scans. The expansion of IP protection supports bioAffinity’s strategy for potential market entry into a region where approximately 1.6 million new lung cancer cases are diagnosed annually. However, the announcement does not include regulatory approvals or commercial agreements related to Hong Kong or China. Clinical data from prior trials show high sensitivity and specificity rates but have not been validated for post-treatment surveillance. While this patent is an important step in protecting bioAffinity’s technology across multiple jurisdictions, it represents a legal milestone rather than immediate revenue generation. Investors are advised to monitor future regulatory submissions and commercialization plans as key indicators of the company's progress.
Tickers: $BIAF
Topics: biotech diagnostics lung_cancer patents